Lawmakers across the political divide have accused the pharma industry of abusing the patent system to keep the prices of their products as high as possible in a combative
A report issued by the office of US Senator Bernie Sanders has claimed that the high prices being charged for new GLP-1 agonist-based obesity therapies like Novo Nordisk’s
The US Federal Trade Commission (FTC) has expanded its campaign against so-called ‘junk’ patents intended to extend market exclusivity and block generic rivals.
California has said it will start selling its own generic version of overdose reversal agent naloxone in another example of the use of government-level purchasing power to
In another setback for the pharma industry, a US federal judge has rejected a bid to overturn the Medicare pricing negotiation brought by Bristol-Myers Squibb and Johnson